Adenosine deaminase activity in patients with renal adenocarcinoma
Open Access
- 1 August 1977
- Vol. 40 (2) , 796-802
- https://doi.org/10.1002/1097-0142(197708)40:2<796::aid-cncr2820400230>3.0.co;2-o
Abstract
Erythrocyte and lymphocyte adenosine deaminase (ADA) levels were studied in 31 patients with renal cell carcinoma (RCC). Decreased lymphocyte ADA levels occurred in patients with RCC. Erythrocyte ADA levels were reduced only in blood type B and O patients. Nephrectomy resulted in a rise in lymphocyte and erythrocyte ADA levels. Progression of clinical disease was associated with a fall in lymphocyte ADA values in all patients and with a rise in erythrocyte levels only in blood type A patients. Our results suggest that changes in erythrocyte and lymphocyte ADA levels in RCC patients are acquired and may offer insight into host‐tumor interactions. Cancer 40:796–802, 1977.This publication has 16 references indexed in Scilit:
- Correction of Severe Combined Immunodeficiency by Fetal Liver CellsNew England Journal of Medicine, 1976
- Adenosine deaminase activity in peripheral blood cells of patients with haematological malignanciesBritish Journal of Cancer, 1976
- In Vitro Assessment of Cell-mediated Immunity in Patients with Renal Cell CarcinomaJournal of Urology, 1976
- Cell-mediated Immunity In Renal Cell Carcinoma—preliminary ReportJournal of Urology, 1976
- Pyrimidine Starvation Induced by Adenosine in Fibroblasts and Lymphoid Cells: Role of Adenosine DeaminaseScience, 1973
- Role of Diffusion Boundary Layer in Contact Inhibition of GrowthNature, 1973
- ADENOSINE-DEAMINASE DEFICIENCY IN TWO PATIENTS WITH SEVERELY IMPAIRED CELLULAR IMMUNITYThe Lancet, 1972
- Cellular and humoral immunity against human malignant melanomaInternational Journal of Cancer, 1971
- Demonstration of cell‐mediated immunity to human neoplasms of various histological typesInternational Journal of Cancer, 1971
- Meaningful clinical classification of therapeutic responses to anticancer drugsClinical Pharmacology & Therapeutics, 1961